

Reference:	FOI.15341.24
Subject:	Treatments
Date of Request:	24 September 2024

Requested:

1. How many patients have been treated for any condition in the last 4 months with the following products?
 - Botox
 - Xeomin
2. How many patients have been treated for Spasmodic Torticollis (ICD-10 Code: G24.3) in the last 4 months with the following products?
 - Botox
 - Xeomin
 - Dysport
3. How many patients have been treated for Neuromuscular dysfunction of bladder (ICD-10 Code N31) in the last 4 months with the following products?
 - Botox
 - Xeomin
 - Dysport
4. How many patients have been treated for Disturbances of salivary secretion (ICD-10 Code K11.7) in the last 4 months with the following products?
 - Botox
 - Xeomin
 - Dysport
5. How many patients have been treated for Clonic Hemifacial Spasm (ICD-10 Code; G51.3) in the last 4 months with the following products?
 - Botox
 - Xeomin
 - Dysport
6. How many patients have been treated for Blepharospasm (G24.5) in the last 4 months with the following products?
 - Botox
 - Xeomin
 - Dysport

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with all of the information requested, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 and the Data Protection (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested for questions 2 to 6, the UHB would need to undertake a manual trawl of the codes provided. As these codes are not unique to the conditions requested, a manual trawl of all records would need to be undertaken, to identify information relevant to your request, as it is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB provides the accessible information it holds below.

1. The UHB provides within the table below, the number of patients treated with the products requested, for any condition, during the period 1 May to 31 August 2024.

Product	Number
Botox	123
Xeomin	0
Dysport	21